Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Regeneron Pharmaceuticals announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2.

It showed reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19.

REGN-COV2 also showed positive trends in reducing medical visits. The ongoing, randomized, double-blind trial measures the effect of adding REGN-COV2 to usual standard-of-care, compared to adding placebo to standard-of-care.

Key findings:

• Serological status highly correlated with baseline viral load

• Serological status at baseline also predicted how rapidly patients had alleviation of their COVID-19 clinical symptoms

• REGN-COV2 rapidly reduced viral load through Day 7 in seronegative patients

• Patients with increasingly higher baseline viral levels had correspondingly greater reductions in viral load at Day 7 with REGN-COV2 treatment

• Patients who were seronegative and/or had higher baseline viral levels also had greater benefits in terms of symptom alleviation

• There were a small number of medically-attended visits given that most non-hospitalized patients recover well at home

• Both doses were well-tolerated: Infusion reactions were seen in 4 patients (2 on placebo and 2 on REGN-COV2). Serious adverse events occurred in 2 placebo patients, 1 low dose patient, and no high dose patients.

Dr. I●●●●●●E G●●●A and 2 other likes this